Weitere Artikel dieser Ausgabe durch Wischen aufrufen
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Intensified competition means that multinational enterprises (MNEs) are increasingly concerned with locating innovation activities in the most appropriate locations. This had led to emerging economies in the South becoming an important destination of R&D-related foreign direct investment (FDI), departing from their traditional role as low-cost production sites. Thus far, however, our understanding of this transformation process is limited. The purpose of this article is therefore to explore the process by which foreign MNEs’ low-value-adding operations in the South are transformed into high-value-adding R&D operations. Drawing on the current literature, we construct a framework of evolution consisting of four major waves of R&D internationalization and corresponding R&D objectives. To better understand how these waves have evolved over time, we focus on the South and trace the process of change using a single historical case study: AstraZeneca in China between 1993 and 2017. We find evidence of idiosyncratic location-bound conditions offering both opportunities and resources. The gradual development of these favourable conditions, along with AstraZeneca’s deepening local knowledge, triggered a transformation process in their operations in China. Our study thus offers important historical insights, which present a platform for future research providing more nuanced theoretical explanations of the four waves of R&D internationalization.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:
Abbott, A. 2001. Time matters: On theory and method. Chicago: University of Chicago Press.
Almeida, P., & Kogut, B. 1999. Localization of knowledge and the mobility of engineers in regional networks. Management Science, 45(7): 905–917. CrossRef
Altenburg, T., Schmitz, H., & Stamm, A. 2008. Breakthrough China’s and India’s transition from production to innovation. World Development, 36(2): 325–344. CrossRef
Archibugi, D., & Iammarino, S. 2002. The globalization of technological innovation: Definition and evidence. Review of International Political Economy, 9(1): 98–122. CrossRef
Asakawa, K., & Ashok, S. 2008. Internationalization of R&D in China and India: Conventional wisdom versus reality. Asia Pacific Journal of Management, 25(3): 375–394. CrossRef
Asiabiotech News. 2007. AstraZeneca enhances clinical research capabilities in China with First Clinical Pharmacology Unit. Asiabiotech News.
AstraZeneca PLC. 2001. Annual report. Cambridge: AstraZeneca PLC.
AstraZeneca PLC. 2002. Annual report. Cambridge: AstraZeneca PLC.
AstraZeneca PLC. 2006. Annual report. Cambridge: AstraZeneca PLC.
AstraZeneca PLC. 2008. Annual report. Cambridge: AstraZeneca PLC.
AstraZeneca PLC. 2009. Annual report. Cambridge: AstraZeneca PLC.
AstraZeneca PLC. 2010. Annual report. Cambridge: AstraZeneca PLC.
AstraZeneca PLC. 2016. Annual report. Cambridge: AstraZeneca PLC.
Athreye, S., Tuncay-Celikel, A., & Ujjual, V. 2014. Internationalisation of R&D into emerging markets: Fiat’s R&D in Brazil, Turkey and India. Long Range Planning, 47(1–2): 100–114. CrossRef
Athreye, S., Batsakis, G., & Singh, S. 2016. Local, global, and internal knowledge sourcing: The trilemma of foreign-based R&D subsidiaries. Journal of Business Research, 69(12): 5694–5702. CrossRef
Awate, S., Larsen, M. M., & Mudambi, R. 2015. Accessing vs sourcing knowledge: A comparative study of R&D internationalization between emerging and advanced economy firms. Journal of International Business Studies, 46(1): 63–86. CrossRef
Bartlett C. A., & Beamish, P. W. 2013. Transnational management: Text, cases & readings in cross-border management, 7th ed. Burr Ridge: McGraw-Hill/Irwin.
Bas, C. L., & Sierra, C. 2002. Location versus home country advantages in R&D activities: Some further results on multinationals’ locational strategies. Research Policy, 31(4): 589–609. CrossRef
Behrman, J. N., & Fischer, W. A. 1980. Overseas R&D activities of transnational companies. International Executive, 22(3): 15–17. CrossRef
Bernstein Research. 2009. Black book—Global pharmaceuticals: Emerging markets should infuse badly needed revenues for years to come: 99–104. New York: Bernstein Global Wealth Management.
Biopharmadive News. 2018. AstraZeneca pins its hopes on China. Biopharmadive News: February 2
Brash, D. T. 1966. American investment in Australian industry. Canberra: Australian National University Press.
Bresciani, S., & Ferraris, A. 2016. Innovation-receiving subsidiaries and dual embeddedness: Impact on business performance. Baltic Journal of Management, 11(1): 108–130. CrossRef
Bruche, G. 2009. The emergence of China and India as new competitors in MNCs’ innovation networks. Competition & Change, 13(3): 267–288. CrossRef
Cantwell, J. 1992. The internationalization of technological activity and its implication for competitiveness. In O. Grandstrand, A. Hakanson, & S. Sjolander (Eds.). Technology management and international business: Internationalization of R&D and technology. Chichester: John Wiley & Sons.
Cantwell, J., & Iammarino, S. 1998. MNCs, technological innovation and regional systems in the EU: Some evidence in the Italian case. International Journal of Economics of Business, 5(3): 383–408. CrossRef
Cantwell, J., & Janne, O. 1999. Technological globalization and innovative centres: The role of corporate technological leadership and locational hierarchy. Research Policy, 28(2/3): 119–144. CrossRef
Cantwell, J., Dunning, J. H., & Lundan, S. M. 2010. An evolutionary approach to understanding international business activity: The co-evolution of MNEs and the institutional environment. Journal of International Business Studies, 41(4): 567–586. CrossRef
Castellani, D., & Zanfei, A. 2006. Multinational firms, innovation and productivity. London: Edward Elgar.
Castellani, D., Jimenez, A., & Zanfei, A. 2013. How remote are r&d labs? Distance factors and international innovative activities. Journal of International Business Studies, 44(7): 649–675. CrossRef
Chemical Market Reporter 2001. AstraZeneca. Opens Plant in China, 259(19): 14–15.
Chen, S. H. 2004. Taiwanese IT firms’ offshore R&D in China and the connection with the global innovation network. Research Policy, 33(2): 337–349. CrossRef
Child, J., Rodrigues, S. B., & Tse, K. K. T. 2012. The dynamics of influence in corporate co-evolution. Journal of Management Studies, 49(7): 1246–1273. CrossRef
Chi-Med. 2017. Chi-Med and AstraZeneca initiate SAVOIR, a global phase III trial of Savolitinib in papillary renal cell carcinoma. Chi-Med News: June 29.
China Daily News. 2018. Innovation at the heart of development. China Daily News: May 24.
China Food & Drug Administration. n.d. Domestic and imported drug database. Beijing: China Food and Drug Administration.
China Ministry of Science and Technology. n.d. S&T programs. Beijing: Ministry of Science and Technology of the People’s Republic of China.
China Pharmaceutical Industry Investment Promotion Report. 2014. Invest in China of Ministry of Commerce of PRC. http://www.fdi.gov.cn. Accessed 8 Oct 2016.
Coe, D. T., Helpman, E., & Hoffmaister, A. W. 1997. North-South R&D Spillovers. The Economic Journal, 107(440): 134–149. CrossRef
Cook, T. D. & Campbell, D. T. (1979) Quasi-experimental design: Design and analysis issues for field settings. Skokie: Rand McNally.
Cordell, A. 1973. Innovation, the multinational corporation: Some implications for national science policy. Long Range Planning, 6: 22–29.
Creamer, D. 1976. Overseas research and development by United States multinationals, 1966–1975. New York: Conference Board.
D’Agostino, L. M. 2015. The neglected effects of R&D captive offshoring in emerging countries on the creation of knowledge at home. Economia e Politica Industriale, 42(1): 61–91. CrossRef
D’Agostino, L. M., & Santangelo, G. D. 2012. Do overseas R&D laboratories in emerging markets contribute to home knowledge creation? Management International Review, 52(2): 251–273. CrossRef
Dhanaraj, C. (2016) Academy of International Business Conference call for paper: The locus of global innovation. https://aib.msu.edu/events/2016/callforpapers.asp], Accessed January 2, 2016.
Dodgson, M. 2009. Asia’s national innovation systems: Institutional adaptability and rigidity in the face of global innovation challenges. Asia Pacific Journal of Management, 26(3): 589–609. CrossRef
Doz, Y. 2011. Qualitative research for international business. Journal of International Business Studies, 42(5): 582–590. CrossRef
Doz, Y. L., Santos, J., & Williamson, P. J. 2001. From global to metanational: How companies win in the knowledge economy. Boston: Harvard Business Press. CrossRef
Dunning, J. H. 1958. American investment in British manufacturing industry. London: Allen and Unwin.
Dunning, J. H. 1998. Location and the multinational enterprise: A neglected factor? Journal of International Business Studies, 29(1): 45–66. CrossRef
Dunning, J. H. 2000. The eclectic paradigm as an envelope for economic and business theories of MNE activity. International Business Review, 9(2): 163–190. CrossRef
Dunning, J. H., & Lundan, S. M. (2008). Multinational enterprises and the global economy. Cheltenham: Edward Elgar.
Dunning, J. H., & Lundan, S. M. 2009. The internationalization of corporate R&D: A review of the evidence and some policy implications for home countries. Review of Policy Research, 26(1–2): 13–33.
Dunning, J. H., & Narula, R. 2005. Multinationals and industrial competitiveness: A new agenda. Cheltenham: Edward Elgar.
Edler, J. 2007. Internationalization of R&D empirical trends and challenges for policy and analysis. Paper presented at the Prime 3rd Annual Conference, Pisa, Italy.
Fan, G., & Wang, X. 2001. NERI Index of Marketization of China by province. Beijing: Economic Science Press.
Feinberg, S., & Gupta, K. 2004. Knowledge spillovers and the assignment of R&D responsibilities to foreign subsidiaries. Strategic Management Journal, 25(8/9): 823–845. CrossRef
Fiercebiotech News. 2017. Riding on booming drug sales, AstraZeneca forms $133m China joint venture. Fiercebiotech News: November 27.
Financial Times. 2015. AstraZeneca pours millions into China R&D. Financial Times.
Fletcher, M., Zhao, Y., Plakoyiannaki, E., & Buck, T. 2018. Three pathways to case selection in international business: A twenty-year review, analysis and synthesis. International Business Review, 27(4): 755–766.
Florida, R. 1997. The globalisation of R&D: Results of a survey of foreign-affiliated R&D laboratories in the USA. Research Policy, 26: 85–103. CrossRef
Gibbert, M., & Ruigrok, W. 2010. The ‘what’ and ‘how’ of case study rigor: Three strategies based on published research. Organizational Research Methods, 13(4): 710–737. CrossRef
Gill, M. J., Gill, D. J., & Roulet, T. J. 2018. Constructing trustworthy historical narratives: Criteria, principles and techniques. British Journal of Management, 29(1): 191–205. CrossRef
Govindarajan, V., & Ramamurti, R. 2011. Reverse innovation, emerging markets, and global strategy. Global Strategy Journal, 1(3–4): 191–205. CrossRef
Govindarajan, V., & Trimble, C. 2012. Reverse innovation: Create far from home, win everywhere. Boston:Harvard Business Press. CrossRef
Greig, S. L. 2016. Osimertinib: First global approval. Drugs, 76(2): 263–273. CrossRef
Griffith, R., Redding, S., & Van Reenen, J. 2004. Mapping the two faces of R&D: Productivity growth in a panel of OECD industries. Review of Economics and Statistics, 86(4): 883–895. CrossRef
Guan, J. C., Yam, R., Tang, E., & Lau, A. 2009. Innovation strategy and performance during economic transition: Evidence in Beijing, China. Research Policy, 38(5): 802–812. CrossRef
Gupta, A. K., & Govindarajan, V. 1991. Knowledge flow patterns, subsidiary strategic roles, and strategic control within MNCs. Academy of Management Proceedings, 1991(1): 21–25. CrossRef
Håkanson, L. 1981. Organization and evolution of foreign R&D in Swedish multinationals. Human Geography, 63(1): 47–56.
Haakonsson, S. J., & Ujjual, V. 2015. Internationalisation of R&D: New insights into multinational enterprises' R&D strategies in emerging markets. Management Revue, 26(2): 101–122. CrossRef
Haour, G., & Jolly, D. 2014. China: The next innovation hot spot for the world. Journal of Business Strategy, 35(1): 2–8. CrossRef
Heathcote, M. 1994. Challenging China. ICIS Chemical Business News: November 14.
Hood, N., & Young, S. 1982. US multinational R&D: Corporate strategies and policy implications for the UK. Multinational Business, 2(1): 10–23.
Ironwood Pharma News. 2018. Ironwood Pharmaceuticals provides fourth quarter and full year 2017 investor update. http://investor.ironwoodpharma.com/news-releases/news-release-details/ironwood-pharmaceuticalsprovides-fourth-quarter-and-full-year-2, Accessed February 15, 2018.
Ito, B., & Wakasugi, R. 2007. What factors determine the mode of overseas R&D by multinationals? Empirical evidence. Research Policy, 36(8): 1275–1287. CrossRef
Jain, S., Nair, A., & Ahlstrom, D. 2015. Introduction to the Special Issue: Towards a theoretical understanding of innovation and entrepreneurship in India. Asia Pacific Journal of Management, 32(4): 835–841.
Jha, S., Dhanaraj, C., & Krishnan, R. 2015. How does multinational R&D evolve in emerging markets?. IMD working paper no. 2015–02, International Institute for Management Development.
Jha, S., Dhanaraj, C., & Krishnan, R. 2018. From arbitrage to global innovation: Evolution of multinational R&D in emerging markets. Management International Review, 58(4): 633–661.
Kuemmerle, W. 1997. Building effective R&D capabilities abroad. Harvard Business Review, 75: 61–72.
Kuemmerle, W. 1999a. Foreign direct investment in industrial research in the pharmaceutical and electronics industries: Results from a survey of multinational firms. Research Policy, 28(1): 179–193. CrossRef
Kuemmerle, W. 1999b. The drivers of foreign direct investment into research and development: An empirical investigation. Journal of International Business Studies, 30(1): 1–24. CrossRef
Kumaraswamy, A., Mudambi, R., Saranga, H., & Tripathy, A. 2012. Catch-up strategies in the Indian auto components industry: Domestic firms’ responses to market liberalization. Journal of International Business Studies, 43(4): 368–395. CrossRef
Lema, R., Quadros, R., & Schmitz, H. 2015. Reorganising global value chains and building innovation capabilities in Brazil and India. Research Policy, 44(7): 1376–1386. CrossRef
Li, X. 2009. China’s regional innovation capacity in transition: An empirical approach. Research Policy, 38(2): 338–357. CrossRef
Liu, M., & Chen, S. 2012. MNCs’ offshore R&D networks in host country's regional innovation system: The case of Taiwan-based firms in China. Research Policy, 41(6): 1107–1120. CrossRef
Liu, F. C., Simon, D. F., Sun, Y. T., & Cao, C. 2011. China's innovation policies: Evolution, institutional structure, and trajectory. Research Policy, 40(7): 917–931. CrossRef
Lu, Y., Tsang, E. W., & Peng, M. W. 2008. Knowledge management and innovation strategy in the Asia Pacific: Toward an institution-based view. Asia Pacific Journal of Management, 25(3): 361–374. CrossRef
Lundvall, B.-Å. 1992. National systems of innovation: An analytical framework. London: Pinter.
Lundvall, B.-Å. 2007. National innovation systems—Analytical concept and development tool. Industry and Innovation, 14(1): 95–119. CrossRef
Mabey, C., & Zhao, S. 2017. Managing five paradoxes of knowledge exchange in networked organizations: New priorities for HRM? Human Resource Management Journal, 27(1): 39–57. CrossRef
Manea, J., & Pearce, R. 2004. Multinationals and transition: Business strategies, technology and transformation in Central and Eastern Europe. Basingstoke: Palgrave-Macmillan. CrossRef
McKinsey 2012. Pharmaceutical innovation: AstraZeneca’s experience in China. McKinsey Quarterly, 1: 93–95.
Meyer, K. E., Mudambi, R., & Narula, R. 2011. Multinational enterprises and local contexts: The opportunities and challenges of multiple embeddedness. Journal of Management Studies, 48: 235–252.
Ministry of Commerce, PRC. 2005. China investment guide: Sweden, invest in China serials, Investment Promotion Agency of Ministry of Commerce Publication. Beijing: Ministry of Commerce, PRC.
Ministry of Commerce, PRC. 2006. I am Jiangsu, invest in China serials, Investment Promotion Agency of Ministry of Commerce Publication. Beijing: Ministry of Commerce, PRC.
Mudambi, R., Piscitello, L., & Rabbiosi, L. 2014. Reverse knowledge transfer in MNEs: Subsidiary innovativeness and entry modes. Long Range Planning, 47(1): 49–63. CrossRef
Mudambi, R., & Santangelo, G. D. 2016. From shallow resource pools to emerging clusters: The role of multinational enterprise subsidiaries in peripheral areas. Regional Studies, 50(12): 1965–1979.
Nair, A., Guldiken, O., Fainshmidt, S., & Pezeshkan, A. 2015. Innovation in India: A review of past research and future directions. Asia Pacific Journal of Management, 32(4): 925–958. CrossRef
Niosi, J. 1999. The internationalization of industrial R&D from technology transfer to the learning organization. Research Policy, 28(2–3): 107–117.
Pearce, R., & Papanastassiou, M. 1997. Global innovation strategies of MNEs and European integration: The role of regional R&D facilities. In R. Pearce (Ed.). Global competition and technology: 123–152. New York: St. Martin’s.
Pearce, R. D., & Papanastassiou, M. 1999. Overseas R&D and the strategic evolution of MNEs: Evidence from laboratories in the UK. Research Policy, 28(1): 23–41. CrossRef
Pearce, R., & Papanastassiou, M. 2006. Multinationals and national systems of innovation: Strategy and policy issues. In A. T. Tavares & A. Teixeira (Eds.), Multinationals, clusters and innovation: Does public policy matter? Basingstoke: Palgrave Macmillan.
Pederson, J. P. 2008. International directory of company histories. Chicago: St. James.
Prabhu, J., & Jain, S. 2015. Innovation and entrepreneurship in India: Understanding jugaad. Asia Pacific Journal of Management, 32(4): 843–868. CrossRef
Prashantham, S., & Dhanaraj, C. 2015. MNE ties and new venture internationalization: Exploratory insights from India. Asia Pacific Journal of Management, 32(4): 901–924. CrossRef
PriceWaterhouseCoopers. 2015. Global innovation 1,000: Innovation’s new world order. PriceWaterhouseCooper PLC.
Reddy, P. 1997. New trends in globalization of corporate R&D and implications for innovation capability in host countries: A survey from India. World Development, 25(11): 1821–1837. CrossRef
Reuters, T. 2010. AstraZeneca CEO sees China growth doubling. Reuters: June 26.
Reuters, T. 2017. AstraZeneca, Chi-Med take kidney cancer drug into final testing. Reuters: June 29.
Rodrigues, S. B., & Child, J. 2008. Corporate Co-Evolution: A Political Perspective, Vol 4. Chichester: John Wiley & Sons. CrossRef
Ronstadt, R. C. 1978. International R&D: The establishment and evolution of research and development abroad by seven US multinationals. Journal of International Business Studies, 9(1): 7–24. CrossRef
Safarian, A. E. 1966. Foreign ownership of Canadian industry. Toronto: McGraw-Hill.
Schmiele, A., & Mangelsdorf, A. 2009. Drivers of international R&D to Asian economies: A perspective from German companies. Paper presented at the 6th Asialics International Conference on “Linkages in Innovation Systems: Global and Local Perspectives,” Hong Kong University of Science and Technology, Hong Kong.
Shin, K., Kim, S. J., & Park, G. 2016. How does the partner type in R&D alliances impact technological innovation performance? A study on the Korean biotechnology industry. Asia Pacific Journal of Management, 33(1): 141–164. CrossRef
Siggelkow, N. 2007. Persuasion with case studies. Academy of Management Journal, 50(1): 20–24. CrossRef
SIPO. 2015. Patent database. Beijing: State Intellectual Property Office, China.
Song, J., & Shin, J. 2008. The paradox of technological capabilities: A study of knowledge sourcing from host countries of overseas R&D operations. Journal of International Business Studies, 39(2): 291–303. CrossRef
Song, J., Asakawa, K., & Chu, Y. 2011. What determines knowledge sourcing from host locations of overseas R&D operations?: A study of global R&D activities of Japanese multinationals. Research Policy, 40(3): 380–390. CrossRef
Tan, X., Liu, X., & Shao, H. 2017. Healthy China 2030: A vision for health care. Value in Health Regional Issues, 12: 112–114. CrossRef
The Independent. 1998. Has Zeneca chosen wisely?. The Independent: December 11.
Turnheim, B., & Geels, F. W. 2012. Regime destabilisation as the flipside of energy transitions: Lessons from the history of the British coal industry (1913–1997). Energy Policy, 50: 35–49. CrossRef
Turnheim, B., & Geels, F. W. 2013. The destabilisation of existing regimes: Confronting a multi-dimensional framework with a case study of the British coal industry (1913–1967). Research Policy, 42(10): 1749–1767. CrossRef
UNCTAD. 2005. World investment report: Transnational corporations and the internationalisation of R&D. New York and Geneva: United Nations.
UNCTAD. 2012. Technology and innovation report. New York and Geneva: United Nations.
UNCTAD. 2016. Investor nationality: Policy challenges. New York and Geneva: United Nations.
Verbeke, A., & Kano, L. 2015. The new internalization theory and multinational enterprises from emerging economies: A business history perspective. Business History Review, 89(03): 415–445. CrossRef
Vernon, R. 1966. International investment and international trade in the product cycle. Quarterly Journal of Economics, 80(2): 190–207. CrossRef
von Zedtwitz, M., & Gassmann, O. 2002. Market versus technology drive in R&D internationalization: Four different patterns of managing research and development. Research Policy, 31(4): 569–588. CrossRef
von Zedtwitz, M., Corsi, S., Søberg, P. V., & Frega, R. 2015. A typology of reverse innovation. Journal of Product Innovation Management, 32(1): 12–28.
Wall Street Journal. 2001a. AstraZeneca, Shanghai University undertake study of schizophrenia. Wall Street Journal: April 11.
Wall Street Journal. 2001b. AstraZeneca invests $100 million in China plant, its biggest in Asia. Wall Street Journal: April 29.
Wang, C., Hong, J., Kafouros, M., & Wright, M. 2012. Exploring the role of government involvement in outward FDI from emerging economies. Journal of International Business Studies, 43(7): 655–676. CrossRef
Washington Business Journal. 2017. MedImmune gets OK from China to pursue arthritis drug in joint venture deal. Washington Business Journal: January 19.
Welch, C., & Piekkari, R. 2017. How should we (not) judge the ‘quality’of qualitative research? A re-assessment of current evaluative criteria in international business. Journal of World Business, 52(5): 714–725. CrossRef
Welch, C., Piekkari, R., Plakoyiannaki, E., & Paavilainen-Mäntymäki, E. 2011. Theorising from case studies: Towards a pluralist future for international business research. Journal of International Business Studies, 42(5): 740–762. CrossRef
World Scientific. 2003. The Asia-Pacific biotech directory. Hackensack: World Scientific.
Yang, Q., & Jiang, C. X. 2007. Location advantages and subsidiaries’ R&D activities in emerging economies: Exploring the effect of employee mobility. Asia Pacific Journal of Management, 24(3): 341–358. CrossRef
Yin, R. K. 2014. Case study research: Design and methods, 5th ed. Thousand Oaks: Sage.
Yu, S. 2011. Information technology in multinational corporations: The managerial role of enterprise resource planning system in headquarters-subsidiary power tussle and local performance. Saarbrücken: Lambert Academic.
Zander, I. 1999. How do you mean ‘global’? An empirical investigation of innovation networks in the multinational corporation. Research Policy, 28(2/3): 195–213. CrossRef
Zeneca Group PLC. 1994. Annual report. London: Zeneca Group PLC.
Zhang, S., & Pearce, R. D. 2011. Multinationals in China: Business strategy, technology and economic development. Basingstoke: Palgrave Macmillan.
Zhang, S., Zhao, S., Bournakis, I., Pearce, R.D., & Papanastassiou, M. 2018. Subsidiary roles as determinants of subsidiary technology sourcing: Empirical evidence from China. Economia Politica, 35(2): 623–648.
Zhou, C., Wang, M., Cheng, Y., Chen, Y., Zhao, Y., Shi, Y. K., & Wu, Y. L. 2017. 1354POsimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated phase II study results including progression-free survival (PFS). Annals of Oncology, 28(S5): Sept. 1.
- The internationalization of innovation towards the South: A historical case study of a global pharmaceutical corporation in China (1993–2017)
- Springer US
Asia Pacific Journal of Management
Print ISSN: 0217-4561
Elektronische ISSN: 1572-9958
Neuer Inhalt/© Stellmach, Neuer Inhalt/© Maturus, Pluta Logo/© Pluta, digitale Transformation/© Maksym Yemelyanov | Fotolia